Détail de l'auteur
Documents disponibles écrits par cet auteur (15)
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) | Mettre toutes les notices dans le panier | Faire une suggestion | Ajouter un critère de recherche
Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis
de Meel RHP, Keene KR, Wirth MA, et al.
Neurology, 2020, 94, 16, e1693
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Hanna MG, Badrising UA, Benveniste O, et al.
The Lancet. Neurology, 2019, 18, 9, p 834
Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy.
Lim J, Rietveld A, De Bleecker JL, et al.
Neurology(R) neuroimmunology & neuroinflammation, 2018, e513
FSHD type 2 and Bosma arhinia microphthalmia syndrome: Two faces of the same mutation
Mul K, Mul K, Lemmers RJLF, et al.
Neurology, 2018
Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis
Lilleker JB, Rietveld A, Pye SR, et al.
Annals of the rheumatic diseases, 2017, 76, 5, p 862
Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis
Badrising UA, Tsonaka R, Hiller M, et al.
Journal of Neuromuscular Diseases, 2017, 4, 4, p 327
Interventions for dysphagia in long-term, progressive muscle disease
Jones K, Pitceathly RD, Rose MR, et al.
Cochrane Database of Systematic Reviews, 2016, 2
A 12-year follow-up in sporadic inclusion body myositis : an end stage with major disabilities
Cox FM, Titulaer MJ, Sont JK, et al.
Brain, 2011, 134, 11, p. 3167-3175
Detecting dysphagia in inclusion body myositis
Cox FM, Verschuuren JJ, Verbist BM, et al.
Journal of neurology, 2009, 256, 12, p. 2009-2013
Possible prognostic factors in the clinical course of patients with inclusion body myositis (Poster)
Collectif, Cox FME, Verschuuren JJG, et al.
Neuromuscular disorders : NMD, 2008, 18, 9-10, p. 771
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo
Badrising UA, Maat-Schieman M, Ferrari MD, et al.
Annals of neurology, 2002, 51, 3, p. 369-372
Dysphagia in IBM. Use of a structured questionnaire and correlation with videofluoroscopic findings
Badrising UA, Maat-Schieman M, van Duinen SG, et al.
Congrès : IX International congress on neuromuscular diseases (30 Aout-4 Sept 1998; Adélaïde)
Muscle & Nerve, 1998, suppl 7, p. s129
Epidemiology of inclusion body myositis in the Netherlands
Badrising UA, Maat-Schieman M, van Duinen SG, et al.
Congrès : 2nd International congress of the World Muscle Society (16-18 Octobre 1997; Tunis)
Neuromuscular disorders : NMD, 1997, 7, 6-7, p. 463
Rp-HPLC fractionation of muscle proteins as an initial step for the identification of autoantigens in inclusion body myositis (IBM)
Verschuuren JJGM, Geleijns CPW, van Noort JM, et al.
Congrès : 2nd International congress of the World Muscle Society (16-18 Octobre 1997; Tunis)
Neuromuscular disorders : NMD, 1997, 7, 6-7, p. 464
The onset and distribution of muscle weakness in inclusion body myositis (IBM)
Badrising UA, Maat-Schieman M, van Duinen SG, et al.
Congrès : 2nd International congress of the World Muscle Society (16-18 Octobre 1997; Tunis)
Neuromuscular disorders : NMD, 1997, 7, 6-7, p. 464
